Biologics for bowel disease face threat from cheaper small molecules
Drug Discovery World
DECEMBER 21, 2023
Adeleke Badejo, Senior Analyst of Immunology at GlobalData, commented: “Barriers to US market growth will primarily result from the loss of patent exclusivity of current biologics, and the subsequent entry of biosimilars to these reference therapies. Fortunately, this will force innovation by companies that seek to enter this space.”
Let's personalize your content